Question 1
The following is an example of a mould
(A) Scedosporium
(B) Candida albicans
(C) Pneumocystis
(D) Mucorales Rhizopus
(E) Treponemum spp
A: Aspergillus and Scedosporium are the two most clinically relevant moulds for the RACP. Scedosporium is a reasonably common mould found in Australia and Spain. RPA Lectures 2015
Question 2 - EMQ
(A) Fluconazole
(B) Voriconazole
(C) Posaconazole
(D) Amphotericin
(E) Caspafungin
(F) Terbinafine
Inhibits squalene epoxidase thereby inhibiting the synthesis of ergosterol
F
An azole antifungal agent used in the salvage treatment of scedosporium
C
An echinocandin that disrupts fungal cell wall synthesis through inhibition of beta-1, 3 D glucan synthesis
E
An antifungal agent that forms pores in the fungal cell wall
D
The first line treatment of invasive aspergillus
B
Invasive pulmonary aspergillosis most commonly occurs in patients with prolonged severe neutropenia. It usually progresses rapidly, and requires prompt administration of systemic antifungal treatment. The choice of antifungal depends on previous antifungal prophylaxis (eg if a patient develops an invasive fungal infection while receiving voriconazole or posaconazole prophylaxis, consider treatment with liposomal amphotericin B)
The following is an example of a mould
(A) Scedosporium
(B) Candida albicans
(C) Pneumocystis
(D) Mucorales Rhizopus
(E) Treponemum spp
A: Aspergillus and Scedosporium are the two most clinically relevant moulds for the RACP. Scedosporium is a reasonably common mould found in Australia and Spain. RPA Lectures 2015
Question 2 - EMQ
(A) Fluconazole
(B) Voriconazole
(C) Posaconazole
(D) Amphotericin
(E) Caspafungin
(F) Terbinafine
Inhibits squalene epoxidase thereby inhibiting the synthesis of ergosterol
F
An azole antifungal agent used in the salvage treatment of scedosporium
C
An echinocandin that disrupts fungal cell wall synthesis through inhibition of beta-1, 3 D glucan synthesis
E
An antifungal agent that forms pores in the fungal cell wall
D
The first line treatment of invasive aspergillus
B
Invasive pulmonary aspergillosis most commonly occurs in patients with prolonged severe neutropenia. It usually progresses rapidly, and requires prompt administration of systemic antifungal treatment. The choice of antifungal depends on previous antifungal prophylaxis (eg if a patient develops an invasive fungal infection while receiving voriconazole or posaconazole prophylaxis, consider treatment with liposomal amphotericin B)
